Document is current
Any future updates will be listed below
-
Authors
Wyatt, Nicola J. https://orcid.org/0000-0001-5050-327X
Speight, R. Alexander https://orcid.org/0000-0003-3184-9181
Stewart, Christopher J. https://orcid.org/0000-0002-6033-338X
Kirby, John A. https://orcid.org/0000-0003-2543-4131
Lamb, Christopher A. https://orcid.org/0000-0002-7271-4956
- License Information
-
More Information
Article History
Accepted: 4 August 2021
First Online: 6 October 2021
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: Dr R Alexander Speight has received grants from Genentech and personal fees from Dr Falk Pharma, Janssen, AbbVie, Tillotts and Takeda, outside the submitted work. Dr Nicola Wyatt, Dr Christopher Stewart, and Prof. John Kirby have no conflicts of interest that are directly relevant to the content of this article. Dr Christopher Lamb has received grants from Genentech, AbbVie, Eli Lilly, Pfizer, Roche, UCB Biopharma, Sanofi Aventis, Biogen IDEC, Orion OYJ and AstraZeneca; personal fees from Dr Falk Pharma and Ferring; and grants and personal fees from Janssen and Takeda, all outside the submitted work.
: Not applicable.
: Not applicable.
: NJW and CAL planned the manuscript content, which was drafted by NJW. CAL provided critical review during manuscript drafting and supervised the work. All other authors (RAS, CJS, and JAK) critically reviewed the manuscript. All authors approved the final manuscript.
: Not applicable.
: Not applicable.
